2022
Variant-specific vaccination induces systems immune responses and potent in vivo protection against SARS-CoV-2
Peng L, Renauer PA, Ökten A, Fang Z, Park JJ, Zhou X, Lin Q, Dong MB, Filler R, Xiong Q, Clark P, Lin C, Wilen CB, Chen S. Variant-specific vaccination induces systems immune responses and potent in vivo protection against SARS-CoV-2. Cell Reports Medicine 2022, 3: 100634. PMID: 35561673, PMCID: PMC9040489, DOI: 10.1016/j.xcrm.2022.100634.Peer-Reviewed Original ResearchConceptsImmune responseImmune cell populationsSARS-CoV-2 spikeAssessment of efficacySARS-CoV-2LNP-mRNABreakthrough infectionsCD8 TImmune profilingMRNA vaccinesPotent protectionT lymphocytesNeutralization activityDelta variantAnimal modelsPotent antibodiesRepertoire diversityCell responsesAuthentic virusSystemic increaseVariant lineagesClonal expansionCell populationsCOVID-19Vaccination
2021
PRL3 induces polyploid giant cancer cells eliminated by PRL3-zumab to reduce tumor relapse
Thura M, Ye Z, Al-Aidaroos A, Xiong Q, Ong J, Gupta A, Li J, Guo K, Ang K, Zeng Q. PRL3 induces polyploid giant cancer cells eliminated by PRL3-zumab to reduce tumor relapse. Communications Biology 2021, 4: 923. PMID: 34326464, PMCID: PMC8322210, DOI: 10.1038/s42003-021-02449-8.Peer-Reviewed Original ResearchConceptsTumor relapsePhase 2 clinical trialStem cell markers SOX2Cell markers SOX2Polyploid giant cancer cellsTumor removal surgeryStem-like cellsAdjuvant immunotherapyGiant cancer cellsPrimary tumorClinical trialsTumor removalCancer cell formationAnimal modelsRelapse tumorsSolid tumorsRelapseRemoval surgeryEmbryonic stem cell markers SOX2TumorsAntibody drugsCancer cellsExtensive DNA damageMetastasisCell survival